Compare Stocks → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CALANASDAQ:CRBPNASDAQ:KINNYSE:LCINASDAQ:UROV Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALACalithera Biosciences$0.03$0.02$0.01▼$0.50$122K-0.17903 shs70 shsCRBPCorbus Pharmaceuticals$39.38+4.5%$35.57$3.03▼$49.87$413.88M2.45789,534 shs59,896 shsKINKindred Biosciences$9.25$9.22$3.46▼$9.28$420.52M1.3840,890 shs178,496 shsLCILannett$1.54$0.64▼$3.72$7.38M0.9592,067 shs280,600 shsUROVUrovant Sciences$16.24$16.23$7.15▼$16.26$531.75M2.36114,469 shsN/A(Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALACalithera Biosciences0.00%-49.90%0.00%-16.50%-37.38%CRBPCorbus Pharmaceuticals-3.92%-11.75%+7.90%+416.44%+326.47%KINKindred Biosciences0.00%0.00%0.00%0.00%0.00%LCILannett0.00%0.00%0.00%0.00%0.00%UROVUrovant Sciences0.00%0.00%0.00%0.00%0.00%SHOCKING Crypto Leak… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCALACalithera BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ACRBPCorbus Pharmaceuticals4.4629 of 5 stars3.53.00.04.72.93.30.6KINKindred BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ALCILannettN/AN/AN/AN/AN/AN/AN/AN/AUROVUrovant SciencesN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCALACalithera BiosciencesN/AN/AN/AN/ACRBPCorbus Pharmaceuticals3.00Buy$52.0032.05% UpsideKINKindred BiosciencesN/AN/AN/AN/ALCILannettN/AN/AN/AN/AUROVUrovant SciencesN/AN/AN/AN/ACurrent Analyst RatingsLatest KIN, CRBP, LCI, CALA, and UROV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/13/2024CRBPCorbus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$51.00 ➝ $58.003/6/2024CRBPCorbus PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$4.00 ➝ $46.001/29/2024CRBPCorbus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$20.00 ➝ $51.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCALACalithera Biosciences$9.75M0.01N/AN/A($0.40) per share-0.06CRBPCorbus Pharmaceuticals$880K470.32N/AN/A($1.56) per share-25.24KINKindred Biosciences$42.16M9.97N/AN/A$1.75 per share5.29LCILannett$340.58M0.00N/AN/A($23.34) per share0.00UROVUrovant SciencesN/AN/AN/AN/A($1.90) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCALACalithera Biosciences-$39.65MN/A0.00∞N/AN/AN/AN/AN/ACRBPCorbus Pharmaceuticals-$44.60M-$10.37N/AN/AN/AN/A-920.31%-111.56%5/14/2024 (Estimated)KINKindred Biosciences-$21.80M-$0.55N/AN/AN/A-529.26%-54.19%-39.76%N/ALCILannett-$231.62M-$18.88N/AN/AN/A-62.40%N/A-13.39%N/AUROVUrovant Sciences-$146.74M-$4.71N/AN/AN/AN/AN/A-162.90%N/ALatest KIN, CRBP, LCI, CALA, and UROV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/12/2024Q4 2023CRBPCorbus Pharmaceuticals-$2.36-$1.81+$0.55-$1.81N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCALACalithera BiosciencesN/AN/AN/AN/AN/ACRBPCorbus PharmaceuticalsN/AN/AN/AN/AN/AKINKindred BiosciencesN/AN/AN/AN/AN/ALCILannettN/AN/AN/AN/AN/AUROVUrovant SciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCALACalithera BiosciencesN/AN/AN/ACRBPCorbus PharmaceuticalsN/A0.740.74KINKindred Biosciences0.197.027.02LCILannettN/A2.231.39UROVUrovant SciencesN/A2.912.91OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCALACalithera BiosciencesN/ACRBPCorbus Pharmaceuticals64.64%KINKindred Biosciences66.89%LCILannett40.28%UROVUrovant Sciences18.44%Insider OwnershipCompanyInsider OwnershipCALACalithera Biosciences6.60%CRBPCorbus Pharmaceuticals4.00%KINKindred Biosciences13.69%LCILannett13.12%UROVUrovant Sciences2.70%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCALACalithera Biosciences84.87 million4.55 millionNot OptionableCRBPCorbus Pharmaceuticals1910.51 million10.09 millionOptionableKINKindred Biosciences6345.46 millionN/AOptionableLCILannett81010.77 million9.35 millionOptionableUROVUrovant Sciences7032.74 millionN/ANot OptionableKIN, CRBP, LCI, CALA, and UROV HeadlinesSourceHeadlineOC Drugmakers Cut Headcounts, Close Officesocbj.com - April 22 at 7:23 PMA2 Bio’s new CEO aims to grow platformpacbiztimes.com - April 8 at 6:15 AMC-Suite Shuffle: A2 Bio, Bayer, BioNTech and Morebiospace.com - March 27 at 2:46 AMA2 Bio Appoints James Robinson as New Chief Executive Officer and Member of the Board of Directorsfinance.yahoo.com - March 26 at 3:06 AMHEALTH BEHAVIOR AND NUTRITION SCIENCESudel.edu - February 17 at 2:30 PMBulletin Science and Security Boardthebulletin.org - February 15 at 3:32 PMSecretary-General’s Guidance Note on Behavioural Scienceun.org - February 5 at 9:35 AMMarine Sciences & Technologyuml.edu - January 7 at 12:52 PMThe 7 Best Science Kits for Kids and Teenspopularmechanics.com - December 22 at 12:32 AMCareers in Computer Sciencemccormick.northwestern.edu - December 11 at 10:18 AMPhD in Information Sciencedrexel.edu - December 8 at 10:01 AMPetauri™ Elects William Fleming and James Robinson to Its Board of Directorsfinance.yahoo.com - December 6 at 10:09 AMCore Requirements & Coursesbc.edu - December 1 at 1:25 PMInspiring Women in Sciencenature.com - November 28 at 10:11 AMDevelop your own cognitive toolkit.miamioh.edu - November 17 at 9:55 AMBenign Prostatic Hyperplasia Market Size in 7MM is expected to witness a major change in the study period 2019–2032, estimates DelveInsightmedgadget.com - November 16 at 8:17 AMPM360 Announces 2023 Trailblazer Award Winnersfinance.yahoo.com - October 4 at 8:59 AMHeavy Drinking Not Tied to Lower Response to DAAs for Hepatitis Cmedpagetoday.com - September 26 at 3:23 PMEledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directorsfinance.yahoo.com - September 11 at 8:30 AMClinical and Translational Science Institutebuffalo.edu - September 8 at 9:36 PMMDxHealth CEO Bullish After Q2 Revenue Boostocbj.com - September 5 at 8:49 PMWindmill Model Science Projecteducation.com - August 15 at 1:51 AMTop Science Newssciencedaily.com - August 10 at 1:52 PMAbout This Sitesciencedaily.com - August 5 at 4:13 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines5 Top-Rated Dividend Stocks With Double-Digit UpsideMarch 25, 2024 11:19 AMView 5 Top-Rated Dividend Stocks With Double-Digit UpsideViking Therapeutics Surges Sentiment for Triple Threat GLP-1PillApril 3, 2024 6:20 AMView Viking Therapeutics Surges Sentiment for Triple Threat GLP-1Pill3 Cheap Stocks That Shouldn’t Be Cheap for Long March 26, 2024 9:49 AMView 3 Cheap Stocks That Shouldn’t Be Cheap for Long 3 Key Stocks Helping to Drive the EV RaceApril 12, 2024 9:25 AMView 3 Key Stocks Helping to Drive the EV RaceHow to Protect your Portfolio Against a Rising VIXApril 10, 2024 9:22 AMView How to Protect your Portfolio Against a Rising VIXAll Headlines Company DescriptionsCalithera BiosciencesNASDAQ:CALACalithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.Corbus PharmaceuticalsNASDAQ:CRBPCorbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.Kindred BiosciencesNASDAQ:KINKindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.LannettNYSE:LCILannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. It offers products in different forms including capsules, tablets, liquids, powders, and sprays. The company was founded in 1942 and is headquartered in Trevose, PA.Urovant SciencesNASDAQ:UROVUrovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. Urovant Sciences Ltd. was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.